Media coverage
99
Media coverage
Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Morningstar.com Country/Territory United States Date 23/05/24 URL https://www.morningstar.com/news/globe-newswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-Tumor Activity Of Novel Costimulatory Bispecific Antibody REGN7075 (Egfrxcd28) In Combination With Libtayo® (Cemiplimab) To Be Reported At ASCO Media name/outlet MENAFN -Press Releases (English) Country/Territory Jordan Date 23/05/24 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Yahoo! Finance Country/Territory United States Date 23/05/24 URL https://finance.yahoo.com/news/promising-anti-tumor-activity-novel-210300569.html Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet ADVFN UK Country/Territory United Kingdom Date 23/05/24 URL https://uk.advfn.com/stock-market/NASDAQ/REGN/share-news/Promising-Anti-tumor-Activity-of-Novel-Costimulato/93918671 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo(TM) (cemiplimab) to be Reported at ASCO Media name/outlet Stockwatch Country/Territory Canada Date 23/05/24 URL www.stockwatch.com/News/Item/U-z9122987-U!REGN-20240523/U/REGN Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo (cemiplimab) to be Reported at ASCO Media name/outlet Wallstreet Online Country/Territory Germany Date 23/05/24 URL https://www.wallstreet-online.de/nachricht/18126802-promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo (cemiplimab) to be Reported at ASCO Media name/outlet Market News Publishing Country/Territory United States Date 23/05/24 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KETK & FOX51 Country/Territory United States Date 23/05/24 URL https://www.ketk.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WWLP.com Country/Territory United States Date 23/05/24 URL https://www.wwlp.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet ABC 27 Country/Territory United States Date 23/05/24 URL https://www.abc27.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KSN Country/Territory United States Date 23/05/24 URL https://www.ksn.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Fox8 Country/Territory United States Date 23/05/24 URL https://fox8.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KRON4 Country/Territory United States Date 23/05/24 URL https://www.kron4.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet 8 News Now Country/Territory United States Date 23/05/24 URL https://www.8newsnow.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WPRI Country/Territory United States Date 23/05/24 URL https://www.wpri.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Binghamton Homepage Country/Territory United States Date 23/05/24 URL https://www.binghamtonhomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WJMN Country/Territory United States Date 23/05/24 URL https://www.upmatters.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WRBL-TV Country/Territory Georgia Date 23/05/24 URL https://www.wrbl.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet YOUR BASIN Country/Territory United States Date 23/05/24 URL https://www.yourbasin.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet INFORMNNY.com Country/Territory United States Date 23/05/24 URL https://www.informnny.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet CW39 NewsFix Country/Territory United States Date 23/05/24 URL https://cw39.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WHNT-TV Country/Territory United States Date 23/05/24 URL https://whnt.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet NBC4 Columbus Country/Territory United States Date 23/05/24 URL https://www.nbc4i.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WLNS Country/Territory United States Date 23/05/24 URL https://www.wlns.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WJBF-TV Country/Territory Georgia Date 23/05/24 URL https://www.wjbf.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WRIC TV Country/Territory United States Date 23/05/24 URL https://www.wric.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WTVW FOX 7 Country/Territory United States Date 23/05/24 URL https://www.tristatehomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WYTV News Country/Territory United States Date 23/05/24 URL https://www.wytv.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Fox 16 Country/Territory United States Date 23/05/24 URL https://www.fox16.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet OzarksFirst.com Country/Territory United States Date 23/05/24 URL https://www.ozarksfirst.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Wavy Country/Territory United States Date 23/05/24 URL https://www.wavy.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet MyPanhandle.com Country/Territory United States Date 23/05/24 URL https://www.mypanhandle.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WTAJ Country/Territory United States Date 23/05/24 URL https://www.wtaj.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KODE TV Country/Territory United States Date 23/05/24 URL https://www.fourstateshomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WCIA.com Country/Territory United States Date 23/05/24 URL https://www.wcia.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WDTN Country/Territory United States Date 23/05/24 URL https://www.wdtn.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KSNT TV Country/Territory United States Date 23/05/24 URL https://www.ksnt.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WDHN Country/Territory United States Date 23/05/24 URL https://www.wdhn.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WKBN 27 First News Country/Territory United States Date 23/05/24 URL https://www.wkbn.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet YourCentralValley.com Country/Territory United States Date 23/05/24 URL https://www.yourcentralvalley.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet FOX 59 Country/Territory United States Date 23/05/24 URL https://fox59.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WFXRTV.com Country/Territory United States Date 23/05/24 URL https://www.wfxrtv.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Big Country Country/Territory United States Date 23/05/24 URL https://www.bigcountryhomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WeAreGreenBay.com Country/Territory United States Date 23/05/24 URL https://www.wearegreenbay.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KNWA Country/Territory United States Date 23/05/24 URL https://www.nwahomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KRQE Country/Territory United States Date 23/05/24 URL https://www.krqe.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet FOX8 WGHP Country/Territory United States Date 23/05/24 URL https://myfox8.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Kark.com Country/Territory United States Date 23/05/24 URL https://www.kark.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet My Champlain Valley Country/Territory United States Date 23/05/24 URL https://www.mychamplainvalley.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WNTZ Country/Territory United States Date 23/05/24 URL https://www.cenlanow.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KTLA Country/Territory United States Date 23/05/24 URL https://ktla.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WREG Country/Territory United States Date 23/05/24 URL https://wreg.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet CW33 NewsFix Country/Territory United States Date 23/05/24 URL https://cw33.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Valleycentral.com Country/Territory United States Date 23/05/24 URL https://www.valleycentral.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WGNO Country/Territory United States Date 23/05/24 URL https://wgno.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet MyHighPlains.com Country/Territory United States Date 23/05/24 URL https://www.myhighplains.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet CBS17.com Country/Territory United States Date 23/05/24 URL https://www.cbs17.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WOWK Country/Territory United States Date 23/05/24 URL https://www.wowktv.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet CBS4Indy Country/Territory United States Date 23/05/24 URL https://cbs4indy.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Rochesterfirst.com Country/Territory United States Date 23/05/24 URL https://www.rochesterfirst.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WJHL.com Country/Territory United States Date 23/05/24 URL https://www.wjhl.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WVNS Country/Territory United States Date 23/05/24 URL https://www.wvnstv.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet FOX5 San Diego Country/Territory United States Date 23/05/24 URL https://fox5sandiego.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WTWO Country/Territory United States Date 23/05/24 URL https://www.mywabashvalley.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WYOU Country/Territory United States Date 23/05/24 URL https://www.pahomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KHON 2 Country/Territory United States Date 23/05/24 URL https://www.khon2.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Fox40 KTXL Country/Territory United States Date 23/05/24 URL https://fox40.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WETM 18 Country/Territory United States Date 23/05/24 URL https://www.mytwintiers.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet CNYHomepage.com Country/Territory United States Date 23/05/24 URL https://www.cnyhomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet OurQuadCities.com Country/Territory United States Date 23/05/24 URL https://www.ourquadcities.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WPHL-TV Country/Territory United States Date 23/05/24 URL https://phl17.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KFOR.com Country/Territory United States Date 23/05/24 URL https://kfor.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet MyStateLine.com Country/Territory United States Date 23/05/24 URL https://www.mystateline.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet FOX 31 News KDVR Country/Territory United States Date 23/05/24 URL https://kdvr.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet KLFY Country/Territory United States Date 23/05/24 URL https://www.klfy.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WSPA.com Country/Territory United States Date 23/05/24 URL https://www.wspa.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet LocalSRY.com Country/Territory United States Date 23/05/24 URL https://www.localsyr.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet ConchoValleyHomepage.com Country/Territory United States Date 23/05/24 URL https://www.conchovalleyhomepage.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WANE-TV Country/Territory United States Date 23/05/24 URL https://www.wane.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet WCBD Country/Territory United States Date 23/05/24 URL https://www.counton2.com/business/press-releases/globenewswire/9122987/promising-anti-tumor-activity-of-novel-costimulatory-bispecific-antibody-regn7075-egfrxcd28-in-combination-with-libtayo-cemiplimab-to-be-reported-at-asco Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet BluegrassLive.com Country/Territory United States Date 23/05/24 URL https://smb.bluegrasslive.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Holliston - Local Town Pages Country/Territory United States Date 23/05/24 URL https://pr.hollistontownnews.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Suffolk News Herald Country/Territory United States Date 23/05/24 URL https://smb.suffolknewsherald.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Luverne Journal Country/Territory United States Date 23/05/24 URL https://smb.luvernejournal.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet TheTidewaterNews.com Country/Territory United States Date 23/05/24 URL https://smb.thetidewaternews.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Times of San Diego Country/Territory United States Date 23/05/24 URL https://pr.timesofsandiego.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Jessamine Journal Country/Territory United States Date 23/05/24 URL https://smb.jessaminejournal.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Leesville Leader Country/Territory United States Date 23/05/24 URL https://smb.theleesvilleleader.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to... Media name/outlet Smithfield Times Country/Territory United States Date 23/05/24 URL https://smb.smithfieldtimes.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet L' Observateur Country/Territory United States Date 23/05/24 URL https://smb.lobservateur.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Kenbridge Victoria Dispatch Country/Territory United States Date 23/05/24 URL https://smb.kenbridgevictoriadispatch.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Elizabethton.com Country/Territory United States Date 23/05/24 URL https://smb.elizabethton.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet LaGrange Daily News Country/Territory Georgia Date 23/05/24 URL https://smb.lagrangenews.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Port Arthur News Country/Territory United States Date 23/05/24 URL https://smb.panews.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet MillisMedway - Local Town Pages Country/Territory United States Date 23/05/24 URL https://pr.millismedwaynews.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Winchester Sun Country/Territory United States Date 23/05/24 URL https://smb.winchestersun.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to Media name/outlet Tryon Daily Bulletin Country/Territory United States Date 23/05/24 URL https://smb.tryondailybulletin.com/article/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayor-cemiplimab-to-be-Reported-at-ASCO?storyId=664faf2d3c6fbf44b4d825e9 Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet Regeneron Country/Territory United States Date 23/05/24 URL https://newsroom.regeneron.com/news-releases/news-release-details/promising-anti-tumor-activity-novel-costimulatory-bispecific Persons Israel Lowy, Title Promising Anti-tumor Activity of Novel Costimulatory Bispecific Antibody REGN7075 (EGFRxCD28) in Combination with Libtayo® (cemiplimab) to be Reported at ASCO Media name/outlet GlobeNewswire Country/Territory United States Date 23/05/24 URL https://www.globenewswire.com/news-release/2024/05/23/2887696/0/en/Promising-Anti-tumor-Activity-of-Novel-Costimulatory-Bispecific-Antibody-REGN7075-EGFRxCD28-in-Combination-with-Libtayo-cemiplimab-to-be-Reported-at-ASCO.html Persons Israel Lowy,